Compare SFIX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFIX | AKBA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.3M | 343.4M |
| IPO Year | 2017 | 2014 |
| Metric | SFIX | AKBA |
|---|---|---|
| Price | $2.94 | $0.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.50 | ★ $4.67 |
| AVG Volume (30 Days) | 1.4M | ★ 8.7M |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.44 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,226,505,000.00 | N/A |
| Revenue This Year | $8.04 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.52 | N/A |
| 52 Week Low | $2.82 | $0.81 |
| 52 Week High | $5.92 | $3.19 |
| Indicator | SFIX | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 47.52 |
| Support Level | $2.99 | $0.84 |
| Resistance Level | $3.51 | $0.96 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 56.25 | 55.62 |
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.